Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Who Is a Candidate for CJC-1295/Ipamorelin Therapy at Perfect B in Doral CJC-1295/Ipamorelin is appropriate for adults aged 30 and above with good baseline health, realistic expectations about the 8-12 week timeline for visible results, commitment to 5-6 day/week injection adherence, and access to baseline labs before starting
Tirzepatide is a prescription medication approved by the FDA for the treatment of type 2 diabetes (marketed as Mounjaro) and chronic weight management (marketed as Zepbound)
Clinical trials show tirzepatide produces greater average weight loss (21% body weight) compared to semaglutide (17% body weight), thanks to its dual GIP/GLP-1 mechanism
The medication might be safe during breastfeeding, but we do not have evidence to confidently state that it is
11 kg body weight reduction in the SURPASS-4 trial), preserve the eGFR slope and reduce the UACR [57, 58]
